Bienvenue dans notre banque interrogeable de ressources et de documentation sur l’approvisionnement plus sécuritaire et autres sujets connexes.
Includes harm reduction tips
Ressources
Handout | 2013
Withdrawal, Harm reduction, About PWUD, Illegal drugs, 2SLGBTQI+, Stimulants, Sex/Gender
Subgroups within the diverse methamphetamine-using population may have distinct treatment needs.
Original research | 2022
Overdose, Harm reduction, Equity, About PWUD, Outcomes, Poverty, Illegal drugs, Stimulants
Cocaine use contines to be a significant public health problem world-wide.
Commentary | 2020
Illegal drugs, Stimulants
Describing substance use practices and elucidating correlates of concurrent use can inform harm reduction service provision and prevent overdose events.
Original research | 2022
Overdose, Policy/Regulatory, About PWUD, Youth, Illegal drugs, Stimulants
This manual was created for providers working in residential community-based withdrawal management services (WMS) to standardize care, improve documentation and information sharing, and provide qui
Webpage | 2021
Withdrawal, About prescribers, Illegal drugs, Substitution/OAT, Stimulants, Harm reduction, Safer supply
Pharmacists Guidelines for risk mitigation in BC from Vancouver Coastal Health
Guidelines | 2020
Clinical guidance, Harm reduction, Policy/Regulatory, Safer supply, About pharmacists, Stimulants, Substitution/OAT, Injecting drugs
Prescriber Guidelines for risk mitigation in BC from Vancouver Coastal Health
Guidelines | 2020
Clinical guidance, Harm reduction, Policy/Regulatory, Safer supply, About prescribers, Stimulants, Substitution/OAT, Injecting drugs
Public health programming designed for this population is limited, particularly in comparison with programming for people who inject drugs.
Original research | 2017
Harm reduction, Illegal drugs, Stimulants
This manuscript describes basic functionality and general specifications of a cocaine-e-cigarette as a medical device treating people with respective cocaine use disorder when cessation and substituti
Original research | 2021
Harm reduction, Safer supply, Illegal drugs, Stimulants, Stigma
Slide deck | 2020
Mortality, Evidence base, Advocacy, Illegal drugs, Indigenous, Stimulants, Sex/Gender
To describe the possible benefits of offering safe supply to people who use drugs during public health emergencies like COVID-19
Commentary | 2020
Safer supply, Stimulants
Infographic | 2021
Overdose, Mortality, Evidence base, Advocacy, Housing, Illegal drugs, Workplace, Rural/remote, Stimulants, Sex/Gender
Update data from the 2020 preliminary report on opioid-related deaths before and during the pandemic
Report | 2021
Overdose, Mortality, Evidence base, Advocacy, Housing, Illegal drugs, Workplace, Rural/remote, Stimulants, Sex/Gender
Quebec safe supply clinical guidance for prescribers
Guidelines | 2020
Overdose, Clinical guidance, Harm reduction, Safer supply, About prescribers, Stimulants, Substitution/OAT, Transitions in care/treatment, Injecting drugs
This article provides a snapshot of data released by Health Canada on opioid- and stimulant-related harms and data from two provinces detailing a concerning trend in the nature of drug toxicity dea
Newsletter | 2021
Overdose, Mortality, Harm reduction, Policy/Regulatory, Safer supply, Decriminalization/legalization, Illegal drugs, Stimulants, SCS/OPS
This qualitative study was conducted to better understand how people who inject drugs (PWID) came to recognize fentanyl as a growing adulterant of heroin and the subsequent sensory discernment strateg
Original research | 2022
Harm reduction, About PWUD, Illegal drugs, Stimulants
Commentary | 2020
Safer supply, Equity, Barriers and enablers, Poverty, Stimulants, Peer/PWLLE program involvement
The clinical guideline was developed to provide key clinical recommendations, as well as clinical guidance on the provision of iOAT.
Guidelines | 2019
Clinical guidance, Policy/Regulatory, Safer supply, About prescribers, Illegal drugs, Stimulants, Transitions in care/treatment, Injecting drugs
To outline the concept of safe supply including its role in drug policy
Commentary | 2019
Harm reduction, Policy/Regulatory, Safer supply, Decriminalization/legalization, Equity, Advocacy, About PWUD, Stimulants
Slide deck | 2020
Clinical guidance, Policy/Regulatory, Safer supply, About prescribers, Stimulants, Substitution/OAT, Transitions in care/treatment
